Gene Therapy, Genome Editing, and Structural Biology for Rare Genetic Diseases
This research community develops gene therapies, genome editing tools, and stem cell treatments for rare genetic disorders, while using high-resolution electron microscopy to determine the structural basis of the proteins involved.
The work centers on adeno-associated virus (AAV) delivery vectors, CRISPR-Cas9 and prime editing technologies, and enzyme replacement therapies. Specific clinical applications include treatments for Pompe disease, alpha-1 antitrypsin deficiency, Duchenne muscular dystrophy, and hemophilia. The community also investigates hematopoietic and pluripotent stem cells for cell-based therapies and utilizes transmission electron microscopy and electron tomography to resolve protein structures and cellular mechanisms.
The community’s output is distributed across a wide range of elements, with the largest share of research appearing in Zinc, Phosphorus, and Carbon, each accounting for approximately 0.1% of their respective element research. Zinc also contributes the highest number of papers to this group, with 268 entries.
The community comprises 11,934 papers, published primarily in Molecular Therapy, bioRxiv (Cold Spring Harbor Laboratory), and Human Gene Therapy.
Recent work focuses on precise integration of large DNA sequences using retargeted serine integrases and prime assembly with linear DNA donors, as well as the development of potency assays for advanced therapy medicinal products.